MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s40266-020-00823-5

Медицинская библиотека · Drugs & aging · 2020

Treatment of Bullous Pemphigoid in People Aged 80 Years and Older: A Systematic Review of the Literature.

Oren-Shabtai Meital, Kremer Noa, Lapidoth Moshe, Sharon Eran, Atzmony Lihi, Nosrati Adi, Hodak Emmilia, Mimouni Daniel, Levi Assi

Систематический обзорСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Bullous pemphigoid commonly affects older adults and has a detrimental effect on both quality of life and longevity. Systemic corticosteroids, the mainstay of therapy, may cause significant adverse effects, especially in older patients. Therefore, safer therapeutic options are being sought.

OBJECTIVE

The objective of this article was to systematically review the published evidence on the efficacy and safety of different treatment modalities for bullous pemphigoid in older patients.

METHODS

We performed a systematic review of all publications until May 2020 in PubMed, Google Scholar, and the ongoing trials registry of the US National Institutes of Health databases evaluating the efficacy and safety of bullous pemphigoid treatments in patients aged older than 80 years. The primary outcome was complete response. The secondary outcomes were partial response, complete remission on minimal therapy or during tapering, recurrence, adverse events, and mortality.

RESULTS

Twenty-eight publications were included: 2 randomized controlled trials, 5 prospective cohort studies, 10 retrospective cohort studies, and 11 case series, with a total of 153 older patients. The overall complete response rate was 31%. Topical corticosteroids had the highest complete response rate (55%) with a low side-effect profile. Biologics (omalizumab and rituximab) were effective in achieving complete remission on minimal therapy (29%) without recurrence, although rituximab was associated with a relatively high mortality rate (29%).

CONCLUSIONS

Current data suggest that topical corticosteroids are effective and safe and should remain the first line of treatment for bullous pemphigoid in older adults. However, their application is difficult and requires a high-functioning patient, third-party assistance, or a relatively mild disease. Biological agents are effective but warrant meticulous patient selection owing to the relatively high mortality rate associated with rituximab.

CLINICAL TRIAL REGISTRATION: PROSPERO registration number CRD42020186686.

Для цитирования: Oren-Shabtai Meital, Kremer Noa, Lapidoth Moshe, Sharon Eran, Atzmony Lihi, Nosrati Adi, Hodak Emmilia, Mimouni Daniel, Levi Assi. Treatment of Bullous Pemphigoid in People Aged 80 Years and Older: A Systematic Review of the Literature.. Drugs & aging. 2020. DOI: 10.1007/s40266-020-00823-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.